InMode entered this earnings release as a medical aesthetics stock that appears inexpensive on a P/E basis but faces a clear question around profit durability. The market reacted with a modest 1% drop to US$15.21. The quarter itself put the focus squarely on pressure in profitability. Net income for Q2 2026 was US$17.1m on revenue of US$95.6m, and trailing net margin now sits at 20.7%, roughly half the level reported a year earlier. For investors, the story starts with that margin squeeze.

Like InMode's medical aesthetics exposure but concerned about the clear margin squeeze and pressure on profit durability? Consider looking at our list of solid balance sheet and fundamentals stocks (50 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$95.6m vs. US$95.6m (broadly flat year on year)
• Net Income, Q2 2026 vs. Q2 2025: US$17.1m vs. US$26.7m (declined about 36%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.29 vs. US$0.42 (declined about 32%)
• Net Margin, Trailing 12 Months vs. Prior Year: 20.7% vs. 44.5% (material compression in profitability)

Prefer clean charts over slogging through dense earnings tables and margin figures for InMode? Get a full visual view of the company, with a focus on its recent profitability and margin trends, in our company report for InMode.

InMode bull case meets slower profit engine

Bulls argue that InMode is a high margin, cash rich medical aesthetics business whose earnings power is being mispriced. Q2 2026 challenges part of that story. Revenue held at US$95.6m year on year, so there is no sign yet of incremental lift from adjacent wellness areas or stronger consumables traction. Net income of US$17.1m on that same revenue base and a trailing net margin of 20.7% that is roughly half last year indicate that the high margin pillar is under pressure. The share price move, a 1% decline to US$15.21 after the release, also does not suggest a strong re rating impulse today. The balance sheet strength and cash argument still matter, but the milestone of showing resilient profitability on flat sales is clearly being missed.

Bear case on margins and demand gains support

Bears frame InMode as a medical aesthetics stock with flattening demand and shrinking profitability that could keep sentiment weak. Q2 2026 gives that concern real numbers. Revenue is flat at US$95.6m compared with Q2 2025, which aligns with fears around limited growth in core procedures. Net income fell from US$26.7m to US$17.1m, and trailing net margin compressed to 20.7% from 44.5%. That is a sharp step down in profit per dollar of sales. The narrative risk that device placements may not be converting into rich, recurring consumables revenue looks more credible when margins halve while revenue stands still. Recent returns are positive over 30 and 90 days, yet the immediate 1% pullback after earnings suggests the market is treating this result as support for the margin pressure story rather than a sign of stabilization.

Access where the surface looks calm but the models start to disagree on InMode's longer term earnings path with the detailed analyst estimates for InMode.

Stay Ahead With Simply Wall St

If the margin squeeze at InMode has you interested but cautious, register for free with Simply Wall St and add it to a Watchlist to track its share price against fair value and watch how profitability trends evolve before deciding on an entry point. Once you own InMode or other stocks, use the Portfolio Command Center to cut through noise and focus on the most important changes to fundamentals and earnings. For a broader view on sentiment and thesis checks over time, tap into thousands of investor viewpoints through the Community. Spot potential catalysts and risks early so you can react quickly and stay ahead of the market.

Seeking Alternatives Beyond InMode Right Now

Fresh stock ideas do not stay quiet for long. Some are already building breakout momentum while others stay under the radar for now. Do not get caught dropping chances; act now.

• Spot potential early breakouts in cash generative companies by reviewing a curated 17 high quality undiscovered gems before those stories start flying across headlines.
• Track income focused opportunities with strong yield support by scanning the hand picked 8 dividend fortresses while prices still reflect today’s expectations.
• Follow structural themes in critical materials by checking the tightly filtered 28 best rare earth metal stocks while the market’s attention is still elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.